Literature DB >> 25308979

Conservative Management of Placenta Accreta/Increta after Vaginal Birth.

S Peiffer1, J Reinhard2, A Reitter1, F Louwen1.   

Abstract

Aim: Aim of the study was to show that conservative management with preservation of the uterus and of fertility is possible in patients with placenta accreta/increta after vaginal delivery. Method: A retrospective analysis of patients with placental attachment disorders after vaginal delivery was done in a perinatal centre between November 2009 and April 2011. The patient collective was identified using the ICD-10 codes for placenta accreta/increta/percreta, and patient records were analysed for risk factors, maternal morbidity, preservation of the uterus and of fertility, and neonatal outcome.
Results: Three cases of placenta increta were identified in the last 1.5 years out of a total of 1457 vaginal deliveries, and all 3 cases were treated conservatively. Mean maternal age was 35.3 years; gestational age ranged from 39 to 41 weeks, and mean duration between delivery of the child and delivery of the placenta was 44.67 days (range: 14-100 days). Two patients developed symptoms of endomyometritis, including fever, leukocytosis and increased CRP levels. All 3 women were successfully managed with preservation of the uterus.
Conclusion: In selected cases with placenta accreta/increta after vaginal delivery, it is possible to avoid surgical procedures, particularly hysterectomy procedures, and successfully manage these patients conservatively with preservation of the uterus.

Entities:  

Keywords:  conservative management; outcome; placenta accreta/increta

Year:  2012        PMID: 25308979      PMCID: PMC4168407          DOI: 10.1055/s-0032-1327827

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN: 0016-5751            Impact factor:   2.915


  8 in total

1.  Maternal outcome after conservative treatment of placenta accreta.

Authors:  Loïc Sentilhes; Clémence Ambroselli; Gilles Kayem; Magali Provansal; Hervé Fernandez; Franck Perrotin; Norbert Winer; Fabrice Pierre; Alexandra Benachi; Michel Dreyfus; Estelle Bauville; Dominique Mahieu-Caputo; Loïc Marpeau; Philippe Descamps; François Goffinet; Florence Bretelle
Journal:  Obstet Gynecol       Date:  2010-03       Impact factor: 7.661

2.  Accuracy of ultrasonography and magnetic resonance imaging in the diagnosis of placenta accreta.

Authors:  Carri R Warshak; Ramez Eskander; Andrew D Hull; Angela L Scioscia; Robert F Mattrey; Kurt Benirschke; Robert Resnik
Journal:  Obstet Gynecol       Date:  2006-09       Impact factor: 7.661

Review 3.  Placenta accreta.

Authors:  Michael A Belfort
Journal:  Am J Obstet Gynecol       Date:  2010-11       Impact factor: 8.661

4.  Abnormal placentation: twenty-year analysis.

Authors:  Serena Wu; Masha Kocherginsky; Judith U Hibbard
Journal:  Am J Obstet Gynecol       Date:  2005-05       Impact factor: 8.661

5.  Clinical risk factors for placenta previa-placenta accreta.

Authors:  D A Miller; J A Chollet; T M Goodwin
Journal:  Am J Obstet Gynecol       Date:  1997-07       Impact factor: 8.661

6.  Fertility and obstetric outcome after conservative management of placenta accreta.

Authors:  Magali Provansal; Blandine Courbiere; Aubert Agostini; Claude D'Ercole; Léon Boubli; Florence Bretelle
Journal:  Int J Gynaecol Obstet       Date:  2010-02-12       Impact factor: 3.561

7.  Medical treatment of placenta accreta with methotrexate.

Authors:  S Arulkumaran; C S Ng; I Ingemarsson; S S Ratnam
Journal:  Acta Obstet Gynecol Scand       Date:  1986       Impact factor: 3.636

8.  Evaluation of sonographic diagnostic criteria for placenta accreta.

Authors:  Hong Soo Wong; Ying Kei Cheung; Jane Zuccollo; John Tait; Kevin C Pringle
Journal:  J Clin Ultrasound       Date:  2008 Nov-Dec       Impact factor: 0.910

  8 in total
  1 in total

1.  Management of patients with placenta accreta in association with fever following vaginal delivery.

Authors:  Liuying Zhong; Dunjin Chen; Mei Zhong; Yutian He; Chunhong Su
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.